World Trade Center Health Program Scientific/Technical Advisory Committee (WTCHP STAC or Advisory Committee), National Institute for Occupational Safety and Health (NIOSH), 81947-81948 [2011-33396]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 250 / Thursday, December 29, 2011 / Notices
for which families of pediatric
inpatients are generally the best or only
judge; for example, the family can best
say if the provider spent sufficient time
with them or explained things in ways
they could understand. Existing
instruments that have been tested
should have a high degree of reliability
and validity; and evidence of wide use
will be helpful.
Dated: December 20, 2011.
Carolyn M. Clancy,
AHRQ Director.
[FR Doc. 2011–33290 Filed 12–28–11; 8:45 am]
BILLING CODE 4160–90–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
World Trade Center Health Program
Scientific/Technical Advisory
Committee (WTCHP STAC or Advisory
Committee), National Institute for
Occupational Safety and Health
(NIOSH)
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463) the Centers for Disease
Control and Prevention (CDC),
announces the following meetings of the
aforementioned committee:
COMMITTEE PUBLIC MEETING TIMES AND
DATES: (All times are Eastern Standard
Time).
1 p.m.–5
p.m., January 24, 2012.
This meeting is available via the USA
toll-free, dial-in number: 1–(888) 801–
1939. To be automatically connected to
the meeting, you will need to enter the
following participant code: 62062756.
PUBLIC COMMENT TIMES AND DATE:
4 p.m.–4:45 p.m., January 24, 2012.
Please note that the public comment
period ends at the time indicated or
following the last call for comments,
whichever is earlier. Members of the
public who want to comment must sign
up by providing their name by mail,
facsimile, email, or telephone, as given
below. Each commenter will be
provided up to five minutes for
comment. A limited number of time
slots are available and will be assigned
on a first come-first served basis.
Written comments will also be accepted
from those unable to attend the public
session.
Status: Open to the public, limited
only by the number of telephone lines.
The conference line will accommodate
up to 100 callers; therefore it is
suggested that those interested in calling
wreier-aviles on DSK3TPTVN1PROD with NOTICES
TELECONFERENCE MEETING:
VerDate Mar<15>2010
15:12 Dec 28, 2011
Jkt 226001
in to listen to the committee meeting
share a line when possible.
Background: The Advisory Committee
was established by Public Law 111–347
(The James Zadroga 9/11 Health and
Compensation Act of 2010, Title XXXIII
of the Public Health Service Act),
enacted on January 2, 2011 and codified
at 42 U.S.C. 300mm–300mm–61.
Purpose: The purpose of the Advisory
Committee is to review scientific and
medical evidence and to make
recommendations to the World Trade
Center (WTC) Program Administrator
regarding additional WTC Health
Program eligibility criteria and potential
additions to the list of covered WTCrelated health conditions. Title XXXIII
of the Public Health Service Act
established within the Department of
Health and Human Services (HHS), the
World Trade Center (WTC) Health
Program, to be administered by the WTC
Program Administrator. The WTC
Health Program provides: (1) Medical
monitoring and treatment benefits to
eligible emergency responders and
recovery and cleanup workers
(including those who are Federal
employees) who responded to the
September 11, 2011, terrorist attacks,
and (2) initial health evaluation,
monitoring, and treatment benefits to
residents and other building occupants
and area workers in New York City who
were directly impacted and adversely
affected by such attacks (‘‘survivors’’).
Certain specific activities of the WTC
Program Administrator are reserved to
the Secretary, HHS, to delegate at her
discretion; other WTC Program
Administrator duties not explicitly
reserved to the Secretary, HHS, are
assigned to the Director, NIOSH. The
administration of the Advisory
Committee established under Section
300mm–1(a) is left to the Director of
NIOSH in his role as WTC Program
Administrator. CDC and NIOSH provide
funding, staffing, and administrative
support services for the Advisory
Committee. The charter was issued on
May 12, 2011, and will expire on May
12, 2013.
MATTERS TO BE DISCUSSED: The agenda
for the Advisory Committee meeting
includes: WTC Health Program Research
Priorities and the petition to add cancer
to the list of WTC Health Program
covered conditions. The agenda is
subject to change as priorities dictate. In
the event an individual cannot attend,
written comments may be submitted.
The comments should be limited to two
pages and submitted to the contact
person below by January 18, 2012.
Efforts will be made to provide the twopage written comments received by the
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
81947
deadline below to the committee
members before the meeting. Comments
in excess of two pages will be made
publicly available at the NIOSH docket
(https://www.cdc.gov/niosh/docket/
archive/docket248.html).
PUBLIC COMMENT SIGN-UP AND
SUBMISSIONS TO THE DOCKET: To sign up
to provide public comments or to
submit comments to the docket, send
information to the NIOSH Docket Office
by one of the following means:
Mail: NIOSH Docket Office, Robert A.
Taft Laboratories, MS–C–34, 4676
Columbia Parkway, Cincinnati, Ohio
45226.
Facsimile: (513) 533–8285.
Email: nioshdocket@cdc.gov.
Telephone: (513) 533–8611.
Submissions to the docket should
reference docket #248.
Policy on Redaction of Committee
Meeting Transcripts (Public Comment):
Transcripts will be prepared and posted
to NIOSH Docket 248 within 60 days
after the meeting. If a person making a
comment gives his or her name, no
attempt will be made to redact that
name. NIOSH will take reasonable steps
to ensure that individuals making
public comments are aware of the fact
that their comments (including their
name, if provided) will appear in a
transcript of the meeting posted on a
public Web site. Such reasonable steps
include: (a) A statement read at the start
of the meeting stating that transcripts
will be posted and names of speakers
will not be redacted; and (b) A printed
copy of the statement mentioned in (a)
above will be displayed on the table
where individuals sign up to make
public comments. If individuals in
making a statement reveal personal
information (e.g., medical information)
about themselves, that information will
not usually be redacted. The CDC
Freedom of Information Act coordinator
will, however, review such revelations
in accordance with the Freedom of
Information Act and if deemed
appropriate, will redact such
information. Disclosures of information
concerning third party medical
information will be redacted.
CONTACT PERSON FOR MORE INFORMATION:
Paul J. Middendorf, Ph.D., Designated
Federal Official, NIOSH, CDC, 4676
Columbia Parkway, MailStop R–45,
Cincinnati, Ohio 45226, Telephone: 1
(888) 982–4748; email: wtcstac@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
Notices pertaining to announcements of
meetings and other committee
management activities, for both the
E:\FR\FM\29DEN1.SGM
29DEN1
81948
Federal Register / Vol. 76, No. 250 / Thursday, December 29, 2011 / Notices
collection of information to OMB for
review and clearance.
Centers for Disease Control and
Prevention, and the Agency for Toxic
Substances and Disease Registry.
Experimental Study on Consumer
Responses to Nutrition Facts Labels
With Various Footnote Formats and
Declaration of Amount of Added
Sugars—(OMB Control Number 0910–
New)
Dated: December 22, 2011.
Ronald Ergle,
Acting Director, Management Analysis and
Services Office Centers for Disease Control
and Prevention.
[FR Doc. 2011–33396 Filed 12–28–11; 8:45 am]
I. Background
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2011–N–0345]
Agency Information Collection
Activities; Submission for Office of
Management and Budget Review;
Comment Request; Experimental
Study on Consumer Responses to
Nutrition Facts Labels With Various
Footnote Formats and Declaration of
Amount of Added Sugars
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a proposed collection of
information has been submitted to the
Office of Management and Budget
(OMB) for review and clearance under
the Paperwork Reduction Act of 1995.
DATES: Fax written comments on the
collection of information by January 30,
2012.
ADDRESSES: To ensure that comments on
the information collection are received,
OMB recommends that written
comments be faxed to the Office of
Information and Regulatory Affairs,
OMB, Attn: FDA Desk Officer, Fax:
(202) 395–7285, or emailed to
oira_submission@omb.eop.gov. All
comments should be identified with the
OMB control number 0910–New and
title ‘‘Experimental Study on Consumer
Responses to Nutrition Facts Labels
With Various Footnote Formats and
Declaration of Amount of Added
Sugars.’’ Also include the FDA docket
number found in brackets in the
heading of this document.
FOR FURTHER INFORMATION CONTACT:
Denver Presley, II, Office of Information
Management, Food and Drug
Administration, 1350 Piccard Dr., PI50–
400B, Rockville, MD 20850, (301) 796–
3793, Denver.Presley@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: In
compliance with 44 U.S.C. 3507, FDA
has submitted the following proposed
wreier-aviles on DSK3TPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:12 Dec 28, 2011
Jkt 226001
Under the Nutrition Labeling and
Education Act of 1990 (Pub. L. 101–
535), the Nutrition Facts label is
required on most packaged foods, and
this information must be provided in a
specific format in accordance with the
provisions of § 101.9 (21 CFR 101.9).
When FDA was determining which
Nutrition Facts label format to require,
the Agency undertook consumer
research to evaluate alternatives (Refs. 1
to 3). More recently, FDA conducted
qualitative consumer research on the
format of the Nutrition Facts label on
behalf of the Agency’s Obesity Working
Group (Ref. 4), which was formed in
2003 and tasked with outlining a plan
to help confront the problem of obesity
in the United States (Ref. 5). In addition
to conducting consumer research, in the
Federal Register of November 2, 2007
(72 FR 62149), FDA issued an advance
notice of proposed rulemaking
(ANPRM) entitled ‘‘Food Labeling:
Revision of Reference Values and
Mandatory Nutrients’’ (the 2007
ANPRM), which requested comments
on a variety of topics related to a future
proposed rule to update the
presentation of nutrients and content of
nutrient values on food labels. In the
2007 ANPRM, the Agency included a
request for comments on how
consumers use the Percent Daily Value
in the Nutrition Facts label when
evaluating the nutritional content of
food items and making purchases.
Research has suggested that
consumers use the Nutrition Facts label
in various ways, including, but not
limited to, using the Nutrition Facts
label to determine if products are high
or low in a specific nutrient and to
compare products (Ref. 6). One
component of the Nutrition Facts label
that serves as an aid in these uses is the
Percent Daily Value. Early consumer
research indicated that the Percent Daily
Value format improved consumers’
abilities to make correct dietary
judgments about a food in the context of
a total daily diet (Ref. 3), which led FDA
to require both quantitative and
percentage declarations of nutrient
Daily Values in the Nutrition Facts label
in the 1993 Nutrition Labeling final rule
(58 FR 2079, January 6, 1993).
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
Research in subsequent years,
however, suggested that consumers’
understanding and use of Percent Daily
Value may be somewhat inconsistent
(Refs. 7 and 8). Additionally, FDA has
received several public comments
suggesting that further research on
Percent Daily Values may be warranted,
along with research on other
modifications to the Nutrition Facts
label. Suggested research on potential
modifications includes research on: (1)
The removal of the statements, ‘‘Percent
Daily Values are based on a 2,000
calorie diet. Your daily values may be
higher or lower depending on your
calorie needs’’; (2) the removal of the
table in the footnote that lists the Daily
Values for total fat, saturated fat,
cholesterol, sodium, total carbohydrate,
and dietary fiber based on 2,000 and
2,500 calorie diets as described in
§ 101.9(d)(9); and (3) changes to the
presentation of and amount of
information provided in the Nutrition
Facts label. Therefore, FDA, as part of
its effort to promote public health,
proposes to use this study to explore
consumer responses to various food
label formats for the footnote area of the
Nutrition Facts label, including those
that exhibit information such as various
definitions for Percent Daily Value, a
succinct statement about daily caloric
intake, and general guidelines for high
and low nutrient levels.
This study will also explore how
declaring the added sugars content of
foods might affect consumers’ attention
to and understanding of the sugars and
calorie contents and other information
on the Nutrition Facts label. FDA is
contemplating requiring the amount of
added sugars to be declared under
sugars with a double indention format
because added sugars are a component
of sugars. This new requirement would
be the first time that the mandatory
declaration of a nutrient is shown in
this format on the Nutrition Facts label.
Because added sugars have been linked
to obesity, a significant public health
problem in the country (Ref. 9), it is
important that this new requirement is
supported by evidence so that
consumers can correctly use the
information. The Agency is not aware of
any existing consumer research that has
examined this topic and is therefore
interested in using this study to enhance
understanding of how consumers would
comprehend and use this new
information.
In the Federal Register of May 23,
2011 (76 FR 29758), FDA published a
60-day notice requesting public
comment on the proposed collection of
information. In that notice, the Agency
announced its intention to examine
E:\FR\FM\29DEN1.SGM
29DEN1
]]>Agencies
[Federal Register Volume 76, Number 250 (Thursday, December 29, 2011)]
[Notices]
[Pages 81947-81948]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-33396]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
World Trade Center Health Program Scientific/Technical Advisory
Committee (WTCHP STAC or Advisory Committee), National Institute for
Occupational Safety and Health (NIOSH)
In accordance with section 10(a)(2) of the Federal Advisory
Committee Act (Pub. L. 92-463) the Centers for Disease Control and
Prevention (CDC), announces the following meetings of the
aforementioned committee:
Committee Public Meeting Times and Dates: (All times are Eastern
Standard Time).
Teleconference Meeting: 1 p.m.-5 p.m., January 24, 2012.
This meeting is available via the USA toll-free, dial-in number: 1-
(888) 801-1939. To be automatically connected to the meeting, you will
need to enter the following participant code: 62062756.
Public Comment Times and Date: 4 p.m.-4:45 p.m., January 24, 2012.
Please note that the public comment period ends at the time
indicated or following the last call for comments, whichever is
earlier. Members of the public who want to comment must sign up by
providing their name by mail, facsimile, email, or telephone, as given
below. Each commenter will be provided up to five minutes for comment.
A limited number of time slots are available and will be assigned on a
first come-first served basis. Written comments will also be accepted
from those unable to attend the public session.
Status: Open to the public, limited only by the number of telephone
lines. The conference line will accommodate up to 100 callers;
therefore it is suggested that those interested in calling in to listen
to the committee meeting share a line when possible.
Background: The Advisory Committee was established by Public Law
111-347 (The James Zadroga 9/11 Health and Compensation Act of 2010,
Title XXXIII of the Public Health Service Act), enacted on January 2,
2011 and codified at 42 U.S.C. 300mm-300mm-61.
Purpose: The purpose of the Advisory Committee is to review
scientific and medical evidence and to make recommendations to the
World Trade Center (WTC) Program Administrator regarding additional WTC
Health Program eligibility criteria and potential additions to the list
of covered WTC-related health conditions. Title XXXIII of the Public
Health Service Act established within the Department of Health and
Human Services (HHS), the World Trade Center (WTC) Health Program, to
be administered by the WTC Program Administrator. The WTC Health
Program provides: (1) Medical monitoring and treatment benefits to
eligible emergency responders and recovery and cleanup workers
(including those who are Federal employees) who responded to the
September 11, 2011, terrorist attacks, and (2) initial health
evaluation, monitoring, and treatment benefits to residents and other
building occupants and area workers in New York City who were directly
impacted and adversely affected by such attacks (``survivors'').
Certain specific activities of the WTC Program Administrator are
reserved to the Secretary, HHS, to delegate at her discretion; other
WTC Program Administrator duties not explicitly reserved to the
Secretary, HHS, are assigned to the Director, NIOSH. The administration
of the Advisory Committee established under Section 300mm-1(a) is left
to the Director of NIOSH in his role as WTC Program Administrator. CDC
and NIOSH provide funding, staffing, and administrative support
services for the Advisory Committee. The charter was issued on May 12,
2011, and will expire on May 12, 2013.
Matters To Be Discussed: The agenda for the Advisory Committee meeting
includes: WTC Health Program Research Priorities and the petition to
add cancer to the list of WTC Health Program covered conditions. The
agenda is subject to change as priorities dictate. In the event an
individual cannot attend, written comments may be submitted. The
comments should be limited to two pages and submitted to the contact
person below by January 18, 2012. Efforts will be made to provide the
two-page written comments received by the deadline below to the
committee members before the meeting. Comments in excess of two pages
will be made publicly available at the NIOSH docket (https://www.cdc.gov/niosh/docket/archive/docket248.html).
Public Comment Sign-Up and Submissions to the Docket: To sign up to
provide public comments or to submit comments to the docket, send
information to the NIOSH Docket Office by one of the following means:
Mail: NIOSH Docket Office, Robert A. Taft Laboratories, MS-C-34,
4676 Columbia Parkway, Cincinnati, Ohio 45226.
Facsimile: (513) 533-8285.
Email: nioshdocket@cdc.gov.
Telephone: (513) 533-8611.
Submissions to the docket should reference docket 248.
Policy on Redaction of Committee Meeting Transcripts (Public
Comment): Transcripts will be prepared and posted to NIOSH Docket 248
within 60 days after the meeting. If a person making a comment gives
his or her name, no attempt will be made to redact that name. NIOSH
will take reasonable steps to ensure that individuals making public
comments are aware of the fact that their comments (including their
name, if provided) will appear in a transcript of the meeting posted on
a public Web site. Such reasonable steps include: (a) A statement read
at the start of the meeting stating that transcripts will be posted and
names of speakers will not be redacted; and (b) A printed copy of the
statement mentioned in (a) above will be displayed on the table where
individuals sign up to make public comments. If individuals in making a
statement reveal personal information (e.g., medical information) about
themselves, that information will not usually be redacted. The CDC
Freedom of Information Act coordinator will, however, review such
revelations in accordance with the Freedom of Information Act and if
deemed appropriate, will redact such information. Disclosures of
information concerning third party medical information will be
redacted.
Contact Person for More Information: Paul J. Middendorf, Ph.D.,
Designated Federal Official, NIOSH, CDC, 4676 Columbia Parkway,
MailStop R-45, Cincinnati, Ohio 45226, Telephone: 1 (888) 982-4748;
email: wtc-stac@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register Notices pertaining to
announcements of meetings and other committee management activities,
for both the
[[Page 81948]]
Centers for Disease Control and Prevention, and the Agency for Toxic
Substances and Disease Registry.
Dated: December 22, 2011.
Ronald Ergle,
Acting Director, Management Analysis and Services Office Centers for
Disease Control and Prevention.
[FR Doc. 2011-33396 Filed 12-28-11; 8:45 am]
BILLING CODE 4163-18-P
